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Abstract
Background: Adenovirus (Ad) mediated gene transfer is a well-established tool to transiently
express constructs in livers of mice in vivo. In the present study, we determined the specificity and
efficiency of Ad vectors expressing short hairpin (sh) RNA constructs to knock-down the estrogen
receptor α (ERα).
Results: Two different shRNA constructs derived from the murine ERα coding sequence were
designed (shERα). In vitro, transfection of three mouse cell lines with pSUPER-shERα constructs
resulted in up to 80% reduction of endogenous ERα activity. A single mismatch in the target
sequence eliminated the reduction of ERα activity, demonstrating the specificity of shERα. The
subsequently generated Ad.shERα vectors were equally effective in vitro.  In vivo, intravenous
administration of Ad.shERα resulted in 70% reduced hepatic mouse ERα mRNA levels. Co-
injection of Ad.shERα with an Ad vector containing a luciferase (luc) gene driven by an estrogen
responsive element (ERE) containing promoter resulted in a significant (90% on day five) down-
regulation of hepatic luciferase activity, as determined by non-invasive optical imaging. Down-
regulation was sustained up to day seven post-injection.
Conclusion: Ad mediated transfer of shERα expression constructs results in efficient and specific
knockdown of endogenous ERα transcription both in vitro and in vivo.
Background
Estrogen exerts various biological effects in numerous
organs throughout the body and has been implicated in
the pathophysiology of a number of diseases including
breast cancer, osteoporosis and cardiovascular disorders.
Most of the estrogenic effects are mediated via the two
known estrogen receptors, ERα and ERβ. These estrogen
receptors are ligand-dependent transcription factors that
can modulate gene transcription directly but also indi-
rectly. Thus far, there is a relative paucity in the descrip-
tion of the role of estrogen and estrogen receptors in
specific organs. Most studies have been performed using
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Affectivity and specificity of pSUPER mediated expression of shERα in mouse cell lines Figure 1
Affectivity and specificity of pSUPER mediated expression of shERα in mouse cell lines. (A+C) The indicated 
mouse cell lines were co-transfected with, ERE-Luc, CMV-LacZ, and pSUPER-empty, pSUPER-shERα_1395, pSUPER- 
shERα_1103, or pSUPER- shERα_tandem. Subsequently, the cells were treated 24 hours with 10-9 M 17-β-estradiol. Luciferase 
activity was measured 48 hours after transfection and after correction for LacZ expression, represented as the mean (n = 3) ± 
SD relative to the transfection with pSUPER-empty. (A) Endogenous mouse ERα mediated transcription in EOMA, H5V and 
MXT cells after introducing pSUPER +/- shERα. (B) The 19-nt target-recognition sequence of ERα_1395 contains one mis-
match with human ERα and five mismatches with the mouse ERβ sequence. (C) ERα mediated transcription in EOMA cells 
after over expression of either mouse ERα- or human ERα-expression vectors in presence of pSUPER empty or pSUPER 
shERα_1395 (D) Western blot analysis of H5V cells co-transfected with pCMV-mERα and pSUPER-empty or pSUPER-
shERα_1395. The lysates were analysed by immunoblotting (insert-photo) with anti-mouse ERα and anti-p38. The intensity of 
the bands was quantified and normalized to cells transfected with pSUPER-empty. The relative ERα protein levels are pre-
sented (bar-diagram) as mean (n = 3) +/- SD.
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non-tissue specific manipulation of ER signaling such as
complete knockouts either via deletion of the estrogen
receptor or via deletion of estrogen production by ovariec-
tomy. The availability of tools to specifically address the
role of ER signaling in individual tissues would thus fill a
void.
Short synthetic duplexes of 21 nucleotides long RNA mol-
ecules can specifically inhibit gene expression in mamma-
lian cells [1]. Because of their efficacy and specificity,
siRNA molecules provide a powerful tool to dissect gene
function. To expand the applicability of the siRNA
approach, Brummelkamp and co-workers [2] have intro-
duced vector-based siRNA expression systems. By direct-
ing the synthesis of shRNA via the polymerase-III H1 RNA
gene promoter, effective siRNA molecules are formed
intracellular after transfection of shRNA expression con-
structs. To further expand the applicability of the siRNA
approach, recombinant retro- and adenoviral based vec-
tors have been designed [3,4]. Of these, adenoviral vectors
offer the advantage of highly efficient infection of a broad
range of cells, independent of active cell division. Moreo-
ver, high titers can be obtained and intravenous injection
results in efficient transduction of the liver.
The present study was designed to generate tools to
address the role of ERα in a tissue- and time- specific man-
ner. To this end, we have developed recombinant Ad vec-
tors encoding shRNA's directed against mouse ERα
(Ad.shERα). Introduction of shERα, either by transfection
or by Ad mediated gene transfer into different murine cell
lines, led to efficient sequence specific repression of ER
mediated transcription. Furthermore, intravenously
administration of Ad.shERα resulted in efficient reduction
of hepatic ERα mRNA levels (P < 0.005) and ERα func-
tionality.
Results
Efficient and specific knock-down of endogenous mERα in 
vitro: Transfection with pSUPER-shERα constructs
Three pSUPER-derived vectors [2] designed to drive
expression shERα sequences were constructed. Two vec-
tors contained sh sequences derived from the boundary of
the DNA binding domain and the hinge region
(shERα_1103), or from the ligand binding domain
(shERα_1395) of mERα, respectively. A third expression
vector contained both the shERα_1103 and shERα_1395
expression cassettes in series (shERα_tandem).
The efficiency of the shERα constructs for reducing endog-
enous ERα activity in vitro was determined using a luci-
ferase reporter assay. For this purpose, the pSUPER-
shERα_1395, pSUPER-shERα_1103, or pSUPER-
shERα_tandem were transfected together with a reporter
plasmid carrying a trimer of ERE plus TATA box upstream
of luciferase (pERE-Luc) into endothelial cell lines
(EOMA and H5V) and in mouse breast cancer cells
(MXT). As shown in Figure 1A, upon transfection with
shERα_1395, relative luciferase activity in lysates of all
three cell lines was reduced by 70–80%. A similar result
was obtained with shERα_1103 in EOMA's. In addition,
the shERα_tandem expression construct proved to be
more efficient than either of single shERα contructs alone
in the EOMA cells, adding some 15% to the 70% reduc-
tion observed with shERα_1395 (Fig. 1A).
To evaluate the specificity of the shERα construct,
shERα_1395 was introduced into EOMA cells over-
expressing either mouse ERα or human ERα. The
ERα_1395 target sequence contains only a single mis-
match with the human ERα (Fig. 1B). Significant suppres-
sion of ERα mediated transcription was only observed in
lysates of cells that were transfected with mouse ERα but
not with human ERα (Fig. 1C). Thus, the observed effects
of shERα_1395 are specific for mouse ERα. Moreover,
changing a single nucleotide in shERα_1395 completely
abolished the silencing effect (data not shown). By west-
ern blotting, the effect of shERα on ERα protein expres-
sion was studied (Fig. 1D). In the presence of
shERα_1395, ERα protein levels were reduced to 33% as
compared to control transfected cells. This reduction cor-
related well with our findings in the luciferase reporter
assay. Thus, the observed inhibition of luciferase activity
upon treatment with shERα_1395 or shERα_1103 is
caused by reduced accumulation of mERα protein. All
together, the shERα_1395 and shERα_1103 expression
vectors are effective and specific in repression of murine
ERα expression.
Knock-down of hepatic ERα expression in vivo: using 
Ad.shERα vectors
To repress ERα activity in vivo, Ad vectors expressing either
shERα_1395 (Ad.shERα_1395), shERα_1103
(Ad.shERα_1103) or both (Ad.shERα_tandem) were gen-
erated (Fig. 2A). The H1 RNA promoter plus shERα
expression cassettes were sub-cloned from the corre-
sponding pSUPER into pAdTrack [5], which is engineered
to co-express GFP enabling the tracking of infected cells.
In addition, we constructed a control AdTrack plasmid,
carrying only the H1 RNA promoter, which allowed for
the generation of Ad.Empty. Prior to the evaluation of
recombinant Ad vectors in vivo, we tested the functional-
ity of the vectors in vitro. EOMA and MXT cells were trans-
fected with pERE-luc, and subsequently infected with
Ad.Empty or the Ad.shERα vectors. Fluorescence analysis
indicated a near 100% infection percentage. The luciferase
experiments (Fig. 2B) were comparable to those obtained
with transfection of the pSUPER constructs (Fig. 1A): both
Ad.shERα vectors repressed luciferase reporter activity upBMC Biotechnology 2006, 6:11 http://www.biomedcentral.com/1472-6750/6/11
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ER-mediated luciferase activity after Ad-mediated transfer of shERα in vitro Figure 2
ER-mediated luciferase activity after Ad-mediated transfer of shERα in vitro. (A) Schematic representation of the 
recombinant Ad vectors, carrying GFP and shERα expression cassettes that were used in this study. (B) EOMA and MXT cells 
were co-transfected with pERE-Luc and pCMV-LacZ and than infected either with Ad.Empty, Ad.shERα_1395, or 
Ad.shERα_1103. 10-9 M Estrogen was administrated for 24 hours. Luciferase activity was measured 48 hours after infection. 
Data represented as mean ± SD relative to infection with Ad.Empty.
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to 90%. Thus, Ad.shERα vectors were found to be fully
functional with respect to repression of mERα activity.
We then proceeded with the application of our vectors in
vivo. The Ad vectors (Ad.Empty, Ad.shERα_1395, or
Ad.shERα_tandem) were injected in the tail vain of
C57Bl/6 mice. This allowed examination of inhibition by
shERα of endogenous hepatic mERα. Four days post-
injection, animals were sacrificed, and the livers were
studied for GFP expression and ERα mRNA level. Similar
GFP expression patterns were observed in all groups, indi-
cating equally efficient transduction (data not shown).
ERα mRNA levels were studied by real time PCR analysis
(Fig. 3). Administration of Ad.shERα_1395 reduced ERα
mRNA levels 70%, whereas hepatic expression of
shERα_tandem resulted in an 85% reduction.
Subsequently, we sought to examine the extent of shERα-
mediated repression of hepatic mERα transcription activ-
ity. For this purpose, we constructed an Ad vector carrying
the estrogen responsive luciferase reporter gene (Ad.ERE-
Luc). First the estrogen-responsiveness of this vector was
determined in vivo (Fig. 4A). Five days post-injection of 8
× 108 pfu Ad.ERE-Luc, the mice were injected s.c with
increasing concentrations of estrogen, ranging from 0 to
50 µg/kg. As shown in Fig 6, 6 hours post-injection, estro-
gen induced hepatic luciferase activity in a dose-depend-
ent manner. Maximal stimulation was reached after
applying 25 µg/kg estrogen. Then, we determined to what
extend Ad.shERα down-regulates the transcriptional activ-
ity of hepatic ERα. Ad.shERα together with Ad.ERE-Luc
reporter vector was administrated intravenously to C57BI/
6 mice. Luciferase expression was detected by a CCD cam-
era in living mice. Without estrogen treatment, all mice
exhibited the same basal expression of the reporter con-
struct (data not shown). Administration of 5 µg/kg estro-
gen, three and seven days after transduction with
Ad.shERα_1103, resulted in a significant repression of
hepatic ERα-mediated luciferase activity (Fig. 4B). These
data were confirmed by measuring luciferase activity in
liver extracts of mice that received estrogen (5 µg/kg, sc)
five days post-injection with Ad.ERE-Luc plus Ad.Empty
or Ad.shERα_1103 (Fig. 4C).
We conclude that Ad-mediated introduction of shERα in
vivo results in an almost complete repression of hepatic
mERα mRNA levels, as well as mERα-mediated transcrip-
tion activity.
Discussion
In this paper, we demonstrate that efficient silencing of
mouse ERα can be achieved in vitro as well as in vivo by use
of Ad-mediated transfer of shRNA molecules that target
the ERα mRNA. Two independent shERα plasmid and Ad
vector expression constructs were generated and shown to
be effective in repressing endogenous ERα activity up to
80% in several different cell lines and in vivo (Fig. 1A, 2B
and 3). In addition, a construct was made expressing both
shERα sequences simultaneously. In vitro as well as in vivo,
this construct was shown to be more effective (Fig. 1A and
3) than either of the two shERα constructs alone. Non-
invasive optical imaging of living mice, allowed us to
quantify shERα activity in vivo. Significant reduction of
mouse ERα transcription levels were observed up to seven
days post-transduction (Fig. 4B).
Thus far, bystander effects caused by shRNA constructs tar-
geted to an unrelated gene have not been reported, and
the specificity of the shERα_1395 construct was verified
by the observation that human ERα, which has a single
mismatch with the murine ERα target sequence, is not
down-regulated (Fig. 1C). The number of mismatches
Hepatic ERα mRNA levels after Ad-mediated transfer of  shERα in vivo Figure 3
Hepatic ERα mRNA levels after Ad-mediated trans-
fer of shERα in vivo. Male C57Bl/6 mice (n = 5) were 
injected with 4 × 109 pfu Ad.Empty, Ad.shERα_1395 or 
Ad.shERα_tandem. Livers were harvested Four days after 
Ad. administration and subjected to taqman analysis. The 
cyclophillin gene was used as internal standard. Data repre-
sented as mean ± SD.BMC Biotechnology 2006, 6:11 http://www.biomedcentral.com/1472-6750/6/11
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Hepatic ERα activity Figure 4
Hepatic ERα activity. (A) Male wt/ C57Bl/6 mice, pre injected with 5 × 108 pfu Ad.LacZ, were injected with 8 × 108 pfu 
Ad.ERELuc. Five days later, the recipients were treated for 6 hours with increasing amounts of estrogen (0–50 µg/kg, s.c). 
Then, the mice were sacrificed, and the livers were processed for luciferase assays. Luciferase activity is expressed as relative 
luciferase units (RLU) per mg total liver protein. (B) Male C57Bl/6 mice (n = 5) were injected with Ad.ERE-Luc (5 × 108 pfu) 
plus Ad.Empty or Ad.shERα_1103 (3 × 109 pfu). Three or seven days post-infection, the mice were injected with 5 µg/kg estro-
gen. The (inset) photo shows the result of optical imaging of the bioluminescence at day three, the bar-diagram is a quantitative 
representation of hepatic luciferase activity at day three or day seven. (C) Male C57Bl/6 mice (n = 5) were co-injected with 
Ad.ERELuc (5 × 108 pfu) + Ad.Empty or Ad.shERα_1103 (3 × 109 pfu). Five days later, the mice received 0 or 5 µg/kg estrogen. 
After 6 hours, the animals were sacrificed, and hepatic luciferase activity was determined. Luciferase activity is expressed as rel-
ative luciferase units (RLU) per mg total liver protein. Data represented as mean ± SD.
A
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with the murine ERβ sequence totals five, making it
unlikely that the shERα_1395 construct would affect
expression of ERβ. Similarly, the shERα_1103 construct
has three mismatches with the human ERα and nine mis-
matches with murine ERβ, making it unlikely that the
shERα_1103 construct would interfere with either of
them. A single mismatch in the shERα_1395 sequence did
render the construct ineffective in down-regulating
murine ERα (data not shown). Thus, the two independent
shERα constructs described here are exquisitely suited to
demonstrate that a specific effect is mediated by down-
regulation of ERα expression and not by down-regulation
of a related sequence.
A key challenge in the application of an shRNA based
approach is efficient delivery of the shRNA constructs to
target cells in vitro and in vivo. For application of shRNA in
vivo, the sh oligopair, driven by H1 RNA polymerase [2] or
U6 promoter [6], can be cloned in viral vectors. Here, the
Ad vector was chosen as delivery vector, because of the rel-
ative ease of generation and amplification. Moreover, the
natural tropism of Ad vectors for the liver enables the
rapid analysis of the hepatic knock-down phenotype.
Since Ad vectors predominantly infect the parenchymal
cells [7,8], it is important to note that most abundant
hepatic ERα expression was detected in parenchymal cells
while ERα expression was barely detected in hepatic
endothelial cells or kupffer cells (data not shown). This
supported the rationale for application of shERα Ad vec-
tors in vivo. Another interesting observation was that upon
administration of 4 × 109 pfu Ad.shERα, an 85% reduc-
tion of ERα mRNA levels was obtained (Fig. 5), whereas
co-injection of 3 × 109 pfu Ad.shERα_1103 with 5 × 108
pfu Ad.ERE-Luc resulted in an almost complete absence of
luciferase activity (Fig. 4C). The ratio of Ad.ERE-Luc versus
Ad.shERα_1103 (1:6) should ensure that all cells that
were transduced by Ad.ERE-Luc also received
Ad.shERα_1103. Thus, the remainder of ERα expression
determined by real-time PCR likely reflects ERα expres-
sion in non-parenchymal and non-infected cells.
Thus far, relative few reports describe the application of
Ad vectors as delivery system for RNAi in vitro [9-12]. Sim-
ilarly, relative few studies on effective RNA interference in
vivo using Ad mediated gene transfer have been reported
[13-15]. One potential explanation for this relative pau-
city in the application of Ad mediated gene transfer for
shRNA expression constructs could lie in the recent obser-
vations of Lu and Cullen [16], that VA1 non-coding RNA,
expressed by wild type adenovirus is a potent inhibitor of
RNA interference. However, replication-incompetent ade-
novirus vectors such as the vectors used in our study have
been reported to express low levels of VA1 [16]. Moreover,
in our hands the effect of the pSUPER shRNA construct
shERα_1935 on reduction of ERα activity in vitro was not
affected by super-infection with the Ad.empty vector (data
not shown). Thus, the Ad vectors applied in this study
seem to have no or a minor inhibitory effect on the RNAi
response in vitro and in vivo. Whether this effect is also
insert specific and/or depends on the particular target
gene remains to be investigated.
The strongest evidence for efficient reduction of endog-
enous hepatic ERα RNA levels in vivo was obtained by co-
injection of Ad.ERE-luc and advanced non-invasive in vivo
optical imaging. Administration of Ad.ERE-luc led to
readily detectable levels of luciferase activity from day 3
up to day 7 and disappeared at day 10 (data not shown).
In agreement with this, the Ad.shERa mediated knock-
down effect was present at day three, five, and seven post-
injection (Fig 4B). This represents a 4 to 5-day window of
expression to determine the phenotypic effects of hepatic
shRNA-mediated reduction of mRNA levels.
Conclusion
We have shown significant repression of hepatic ERα
activity in mice utilizing Ad.shERα vectors. In addition,
using advanced non-invasive optical imaging technology,
the dynamics of the knock-down effect in vivo have been
demonstrated. Thus, our data confirm that application of
shRNA represents a powerful tool for targeted gene silenc-
ing. We conclude that Ad-mediated delivery of shERα
constructs represents an elegant tool to gain more insight
in the role of the hepatic ERα.
Methods
Plasmids
Two oligonucleotide pairs (mERα_1395: 5'-
gatccccgctcctgtttgctcctaacttcaagagagttaggagcaaacag-
gagctttttggaaa-3' and 5'-
agcttttccaaaaagctcctgtttgctcctaactctcttgaagttaggagcaaacag-
gagcggg-3', mERα_1103: 5'-gatccccgaatagccctgccttgtcc
ttcaagagaggacaaggcagggctattc tttttggaaa-3' and 5'-agc
ttttccaaaaagaatagccctgccttgtcctctcttgaaggacaaggcagggctat-
tcggg) were ordered (Eurogentec, United kingdom). The
bold nucleotides correspond to nucleotides 1395–1418
and 1103–1120 of the mRNA mERα sequence (GenBank
accession number NM_ 007956). The underlined nucle-
otides represent a BglII and a HindIII site. These oligo's
were annealed and ligated between the BglII and HindIII
sites of pSUPER-H1prom [2]. The pSUPER-shERα
sequences were verified by restriction and sequence anal-
ysis (ABI 3700, LGTC, Leiden).
The H1prom plus or minus shERα were cloned from the
pSUPER into the promoter less pAdTrack vector [5] by use
of XbaI and XhoI restriction sites. The Ad.shERα_tandem
construct was generated by ligation of H1prom-
shERα_1103 between the NotI and KpnI sites of pTrack-
H1prom- shERα_1395.BMC Biotechnology 2006, 6:11 http://www.biomedcentral.com/1472-6750/6/11
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The (ERE)3TATA-Luc was cloned from pGl3-basic as a
ClaI-blunt/ KpnI fragment in EcoRV- and KpnI- digested
promoter less Shuttle vector (pShuttle) (He et al. 2509–
14). The functionality of this construct was verified by
transfection. hERα was cloned from pCMV5 (pCMV5-
hERα) [17] as a BamHI  fragment in the BglII  digested
pShuttle-CMV vector. The pcDNA3.1-mERα expression
vector was provided by Larry Jameson [18] and subcloned
as a EcoRI-blunt fragment in the EcoRV digested pShuttle-
CMV vector.
Cell culture
The MXT+ (murine breast cancer) cell line was generously
provided by Dr. Bernards. H5V (a murine endothelial cell
line derived from heart), EOMA (murine hemangioma-
derived micro vascular cell line) and MXT cells were main-
tained in Dulbecco's modified Eagle's medium (DMEM)
(Gibco BRL) supplemented with 10% fetal calf serum,
100 units/ml Penicillin, 100 µg/ml Streptomycin and
glutamax (Invitrogen) (Complete DMEM). PERC6 cells
[19] were maintained in complete DMEM supplemented
with 10 mM MgCl2+. For large-scale production of recom-
binant Ad in PERC6 cells (Crucell, Leiden, he Nether-
lands), complete DMEM with 2% horse serum (Gibco)
was used.
Luciferase reporter assays
Transient transfections were performed in triplicate in 12-
wells plates (1.105 cells per well) using Lipofectamine
(Invitrogen). The effect of shERα on ERα mediated tran-
scription regulation was determined by co-transfecting
the cells with 100 ng of reporter construct (ERE)3TATA-
LUC and 500 ng expression vector pSUPER-shERα or an
empty pSUPER control vector together with 100 ng
pCMV-LacZ. After 24 hours, the cells were stimulated with
complete DMEM containing 10-9M Estrogen for an addi-
tional 24 hours. The cells were lysed with reporter lyses
buffer (Promega) and after centrifugation of 2 min, super-
natant was used for determining β-galactosidase normal-
ized luciferase activity by adding 100 µl luciferyl-CoA
(Promega) to 20 µl of cell extract in a monolight lumi-
nometer (BD Biosciences). β-galactosidase was measured
in a 96-well microtiter plate using the β-Galactosidase
Enzyme Assay System in reporter lyses buffer (Promega).
Absorbance at 450 nm was determined in a microplate
reader. Luciferase activities were normalized for transfec-
tion efficiency with the β-galactosidase activity and
expressed as a percentage relative to expression levels
induced by endogenous estrogen receptor (ER). Expres-
sion of endogenous ERα in those cells was verified by real
time PCR.
Western blot analysis
Immunoblotting procedures were as described previously
[20]. H5V cells seeded in triplicate in 12-wells plate were
co-transfected with 20 ng pCMV-mERα and 500 ng
expression vector pSUPER-shERα or an empty pSUPER
control vector as described above. 28 hours post-transfec-
tion, the cells were lysed in 200 µl of RIPA buffer (1%
NP40, 0.5% DOC, 0.1% SDS, 50 mM Tris pH 8.0, 150
mM NaCl, 2.5 mM EDTA) containing protease inhibitor
(40 ul/ml, Roche). Extracts were cleared by centrifugation
(4°C, 14 000 g, 5 min), and protein content was deter-
mined using the BCA kit (Pierce). Protein samples were
denaturated (5 min, 90°C) and separated on SDS/PAGE
by use of 8% gradient gels and were transferred to polyvi-
nylidene difluoride (PVDF) membranes (Millipore, Ger-
many). Blots were stained with Ponceau S before blocking
to verify equal loading and appropriate protein transfer.
Membranes were blocked for 90 min in PBS, pH 7.4, con-
taining 0.05% Tween 20 and 10% milk powder. Thereaf-
ter, membranes were incubated for 16 h at 4°C with ab
MC20, 1:1000 (mERα rabbit polyclonal antibody, Santa
Cruz Biotechnology, CA). After extensive washing with
blocking buffer without milk powder or BSA, membranes
were incubated for 2 h with horseradish peroxidase-con-
jugated goat anti-rabbit IgG, 1:5000 (Promega). Mem-
branes were again extensively washed and bound
peroxidase conjugates were visualized by enhanced
chemiluminescence (ECL, Amersham) on a LumiImager
workstation. Additionally, filters were stripped by a 30
min incubation in 100 mM β-mercaptoethanol, 2% SDS,
62.5 mM Tris-HCl pH 6.8 at 50°C, to proceed with the
whole procedure as described above. However, now
membranes were incubated for 16 h at 4°C with p-38 ab,
1:1000 (N-20, cs-728, rabbit polyclonal antibody, Santa
Cruz Biotechnology, CA). Immunoblots were quantified
using LUMIANALYST software on a LumiImager (Boe-
hringer-Mannheim).
Adenoviral vectors
Recombinant adenoviral plasmids were generated by
homologous recombination of pAdtrack or pShuttle vec-
tors with pAdEasy1 in BJ5183 cells as described previously
[5]. Correct clones were propagated in DH5α cells (Life
Technologies). For the generation of the Ad.shERα vec-
tors, Ad.Empty and Ad.ERE-Luc, PERC6 cells were trans-
fected with 4 µg Pac-I-linearized adenoviral construct
using LipofectAMINE PLUS (Life Technologies). After 16
hours transfection medium was replaced by growth
medium. Transfected cells were harvested at day seven
post-transfection and after three freeze-thaw cycles the
lysate was used for large-scale production of Ad vectors in
PERC6 cells. Virus was purified by double CsCl centrifu-
gation and subsequently dialysed as described previously
[21]. Final yields as assessed by plaque assays on 911 cells
were approximately 2 × 1010 plaque forming units (pfu)/
ml. The control virus (Ad.Empty) carries the green fluores-
cent protein (GFP) under control of cytomegalovirus pro-
moter (CMV) and contained the H1prom.BMC Biotechnology 2006, 6:11 http://www.biomedcentral.com/1472-6750/6/11
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Ad.shERα_1395 and Ad.shERα_1103 carry GFP under
control of CMV and shERα_1395 or shERα_1103 under
control of H1prom. Ad. shERα_tandem carries both
shERα_1395 and shERα_1103 under control of their own
H1prom. Ad.ERE-Luc does not contain CMV-GFP and its
functionality was verified in vitro and in vivo.
Infection cells
24 hours before transfection, 1.105 cells per well were
seeded into12 wells-plate. Cells were transiently trans-
fected by use of lipofectamine with a total of 450 ng of
DNA per well (150 ng of reporter plasmid (ERE)3TATA-
LUC and 300 ng pCMV-LacZ). After 4 hours cells were
infected with either Ad.shERα or control Ad.Empty (MOI
5.000). Additionally, they received 10-9M estrogen for 24
hours. Cells were lysed in 300 µl reporter lyses buffer. β-
galactosidase and luciferase activity was determined as
described above.
Animals and Ad Injection
The Ethics Committee for Animal Experiments of the Lei-
den University approved all animal work and the experi-
mental protocols complied with the national guidelines
for use of experimental animals. Male C57Bl/6JIco
(Charles river, The Netherlands) were given a standard m
diet Chow (Hope Farms, Woerden, NL) and housed
under standard conditions in conventional cages with free
access to water and food.
Recombinant Ad, with a maximum of 4 × 109 pfu in 200
µl of PBS, were administered by injection into the tail vein
of mice at the age of 14 weeks. Within five days post-infu-
sion, mice were sacrificed; liver pieces were removed and
immediately deep-frozen in liquid nitrogen and stored at
-80°C.
Pharmacological treatment
The experiment was carried out in 12-wks old C57BL/6
male mice. To prevent sequestration of low doses of
Ad.ERE-Luc by liver Kupffer cells, mice were pre-injected
with Ad.LacZ (5 × 108 pfu) 4 hours before administration
of 8 × 108 pfu Ad.ERE-Luc. 17β-estradiol (Sigma, E8875)
was dissolved in sesame oil (Sigma). In the dose-response
experiment, five days post-injection of Ad.ERE-Luc, 0, 5,
25 and 50 µg/kg 17β-estradiol was injected for 6 hours.
Then liver pieces were rapidly dissected and immediately
deep-frozen in liquid nitrogen and stored at -80°C for fur-
ther analysis.
Bioluminescent reporter imaging
The experiment was carried out in 12 wks old C57BL/6
male mice co-injected with Ad.ERELuc (5 × 108 pfu) plus
either Ad.Empty or Ad.shERα (3 × 109 pfu). Biolumines-
cent signals (BLS) were performed at time 0 and at several
days after 6 and 24 hours s.c injections of 5 µg/kg 17 β-
estradiol with the Xenogen IVIS imaging system (IVIS
100). The living mice were intraperitoneal (ip) injected
with the luciferase substrate, luciferin, at a dose of 150
mg/kg body weight approximately 5 minutes before imag-
ing. The mice were anaesthetized with isoflurane/oxygen
and placed on the imaging stage. Total photon emission
of each animal was acquired for 1 minute. Captured
images were then quantified by using the Living Image
software (Xenogen Corp, Almeda, CA) and the IGOR soft-
ware (WaveMetrics Corp, Lake Oswego, OR). BLS from
the region of interest (ROI) was expressed using the
pseudo colour scale (Red most intense and Blue least
intense luminescence) and the data were presented as the
cumulative photon counts collected within each ROI.
Because layers of tissue may limit photon emission from
inner organs, the experiment was repeated. Of these mice
the livers were rapidly dissected at day 5, 6 hours after
17β-estradiol administration, verifying the results from
the bioluminescent reporter imaging by determining the
luciferase activity in liver lysates
Luciferase enzymatic assay
The liver extracts were prepared by homogenisation with
the minibead beater in reporter lyses buffer (Promega),
two cycles of freeze-thawing and 2 min. of centrifugation
at maximum speed. Supernatants were used for determin-
ing protein-normalized luciferase activity by adding 100
µl luciferyl-CoA (Promega) to 20 µl of liver extract in a
monolight luminometer (BD Biosciences). Protein con-
tent was measured in a 96-well microtiter plate using the
BCA protein assay kit (Pierce). Absorbance at 562 nm was
determined in a microplate reader.
Real time quantitative PCR analysis
Total RNA was extracted from liver using TRIzol reagent
(Life technologies). Purified RNA was treated with RQ1
RNase-free DNase (Promega, 1 units/2 µg of total RNA)
and reverse transcribed with SuperScript II Reverse Tran-
scriptase (Invitrogen) according to the manufacturer's
protocol. Quantitative gene expression analysis was per-
formed on an ABI prism7700 Sequence Detection System
(Applied Biosystems) using SYBR Green as described ear-
lier (Hoekstra et al. 25448–53). PCR primer sets (Cyclo-
philline, Fw: AAAAGGAAGACGACGGAGCC Rev:
TCGGAGCGCAATATGAAGGT and mERα, Fw: CTAGCA-
GATAGGGAGCTGGTTCA, Rev: GGAGATTCAAGTC-
CCCAAAGC) were designed via Primer Express 1.7
software with the manufacturer's default settings (Applied
Biosystems) and were validated for amplification effi-
ciency. The absence of genomic DNA contamination in
the RNA preparations was confirmed in a separate PCR
reaction on total RNA samples that were not reverse tran-
scribed. Cyclophilline was used as a control.Publish with BioMed Central    and   every 
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Data Analysis – The significance of differences in relative
gene expression numbers Ct (Ct((Cyclo)-Ct(target gene)) meas-
ured by real time quantitative PCR was calculated using a
two-tailed Student's t  test. Probability values less than
0.05 were considered significant.
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